Are you spending too much on lifecycle costs?

February 5, 2015 by ,

On the Blog: When it comes to risk-based testing, are you missing out on savings opportunities? In today's blog, Fred Bickel offers insight as to what savings you may be overlooking.

ASTM E2500 – Risk-based testing has been in play for several years now.  By design, there is a significant opportunity to avoid many lifecycle costs without creating an adverse impact to quality or processes.  These cost-saving opportunities may not be obvious at first glance but upon a closer look, they are real and tangible savings.

Before we look at how to attain the potential savings, we should first explore the process for determining criticality of a system.  Determining criticality is basically answering a series of questions about the system.  Below are some examples that have been used in the industry to help determine whether a system is critical or non-critical.

Does the system contain components or perform functions that serve to meet one or more process requirements including Critical Process Parameters (CPP)?

Does the system have direct contact with the prodct or process stream (including excipients, ingredients, and/or solvents), and such contact has the potential to impact the final product quality or pose a risk to patients?

Does the system provide an excipient or produce an ingredient or solvent (e.g., water for injection), and the quality (or lack thereof) of this substance could impact the final product quality or pose a risk to patients?

Is the system used in cleaning, sanitizing or sterilizing, and could the malfunction of the system result in failure to adequately clean, sanitize, or sterilize, such that a risk to patients would result?

Does the system control a risk to the patient by establishing a proper environment (e.g., nitrogen blanket, closed process, exposed-filling-zone air quality, maintenance of temperature, humidity, when such parameter is part of the product CPPs)?

Does the system produce, process, or store data used to accept or reject product critical process parameters, or electronic records subject to 21 CFR Part 11 and EU GMP Vol. 4, Annex 11 respectively?

Does the system provide container closure or product protection, the failure of which would pose a risk to patients or degradation of product quality?

Does the system provide product identification information (e.g., lot number, expiration date, counterfeit prevention features)?

If any of these questions are True, then the system is likely critical and should be tested and maintained as such.  If that is not the case however, then a savings can potentially be realized.

When performing impact assessments, a typical outcome results in a listing of instruments that are either critical or non-critical.  Ensuring that only critical instruments fall into the routine calibration program can lead to substantial savings, especially over time.  Let’s look at that concept in further detail:

Latest Posts

Understanding the New Combination Product PMSR Guidance Documents and Impact on Industry
April 3, 2018

On March 20, 2018, the US Food and Drug Administration (FDA) released two new guidance…

Read More Pharmacovigilance

Related Posts

Contact Us